Eone Diagnomics Genome Center Past Earnings Performance
Past criteria checks 0/6
Eone Diagnomics Genome Center's earnings have been declining at an average annual rate of -35.4%, while the Life Sciences industry saw earnings growing at 22.4% annually. Revenues have been growing at an average rate of 12% per year.
Key information
-35.4%
Earnings growth rate
-31.4%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 12.0% |
| Return on equity | -55.1% |
| Net Margin | -53.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
There's No Escaping Eone Diagnomics Genome Center Co., Ltd.'s (KOSDAQ:245620) Muted Revenues Despite A 43% Share Price Rise
Feb 29
Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06If You Had Bought Eone Diagnomics Genome Center (KOSDAQ:245620) Shares A Year Ago You'd Have Earned 54% Returns
Feb 24Do Insiders Own Lots Of Shares In Eone Diagnomics Genome Center Co., Ltd. (KOSDAQ:245620)?
Jan 20Eone Diagnomics Genome Center (KOSDAQ:245620) Is Carrying A Fair Bit Of Debt
Dec 16Revenue & Expenses Breakdown
How Eone Diagnomics Genome Center makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 73,966 | -39,884 | 13,825 | 2,575 |
| 31 Dec 23 | 88,457 | -33,027 | 13,216 | 2,702 |
| 30 Sep 23 | 100,554 | -30,791 | 13,157 | 2,674 |
| 30 Jun 23 | 99,636 | -37,705 | 13,981 | 3,300 |
| 31 Mar 23 | 96,173 | -24,102 | 13,908 | 3,256 |
| 31 Dec 22 | 94,244 | -29,865 | 14,772 | 4,509 |
| 30 Sep 22 | 91,964 | -39,728 | 17,201 | 5,241 |
| 30 Jun 22 | 95,540 | -30,075 | 17,542 | 5,211 |
| 31 Mar 22 | 90,842 | -22,796 | 17,931 | 5,083 |
| 31 Dec 21 | 89,282 | -20,667 | 17,526 | 4,371 |
| 30 Sep 21 | 91,354 | -9,238 | 16,164 | 6,334 |
| 30 Jun 21 | 95,302 | -6,556 | 18,618 | 5,684 |
| 31 Mar 21 | 99,049 | -11,570 | 20,518 | 3,970 |
| 31 Dec 20 | 92,541 | -10,398 | 20,279 | 3,614 |
| 30 Sep 20 | 80,840 | -4,399 | 19,974 | 1,118 |
| 30 Jun 20 | 65,727 | -10,713 | 14,869 | 1,242 |
| 31 Mar 20 | 59,647 | -10,518 | 11,274 | 2,079 |
| 31 Dec 19 | 56,722 | -9,802 | 10,567 | 1,667 |
| 30 Sep 19 | 55,273 | -8,765 | 10,910 | 1,771 |
| 30 Jun 19 | 46,550 | -8,500 | 9,976 | 1,908 |
| 31 Mar 19 | 30,772 | -8,207 | 8,612 | 1,957 |
| 31 Dec 18 | 21,497 | -7,602 | 7,111 | 1,855 |
| 30 Sep 18 | 8,953 | -7,113 | 5,900 | 1,984 |
| 30 Jun 18 | 5,183 | -5,948 | 4,687 | 1,914 |
| 31 Mar 18 | 4,827 | -5,692 | 4,702 | 970 |
| 31 Dec 17 | 3,235 | -6,286 | 4,385 | 1,500 |
| 31 Dec 16 | 1,393 | -3,867 | 2,278 | 1,128 |
Quality Earnings: A245620 is currently unprofitable.
Growing Profit Margin: A245620 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A245620 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare A245620's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A245620 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.9%).
Return on Equity
High ROE: A245620 has a negative Return on Equity (-55.11%), as it is currently unprofitable.